Science Explorer Back to mapMap
Discussion
Topic · Oncology

Clusterin in disease pathology

Clusterin in disease pathology is a research topic within Oncology. Science Explorer counts 4.8k research works in it since 1954. 10.2% of them reached the world's top 10% most cited for their field and year.

This cluster of papers explores the multifaceted role of Clusterin, a chaperone protein, in cancer development, progression, and therapy. It investigates its involvement in apoptosis inhibition, TGF-ß signaling modulation, angiogenesis promotion, chemoresistance, and its potential as a biomarker for various cancers. The papers also discuss the implications of Clusterin in metastasis, particularly in prostate cancer.

  • Clusterin
  • Chaperone
  • Apoptosis
  • Cancer
  • Metastasis
  • TGF-ß Signaling
  • Angiogenesis
  • Prostate Cancer
  • Chemoresistance
  • Biomarker
Research works
4.8k
fractional, since 1954
In the world top 10%
486
per year above
Top-10% rate
10.2%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+69%
the tick is no change
Largest producer
China
64% of the 10 largest, 2022-now
Clusterin in disease pathology

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Clusterin in disease pathology research?

By volume, China and the United States publish the most (796 and 190 works in 2022-now).

By volume, 2022-now

  1. 1 China 796 works
  2. 2 United States 190 works
  3. 3 Japan 63 works
  4. 4 India 39 works
  5. 5 United Kingdom 34 works
  6. 6 Germany 33 works
  7. 7 Türkiye 25 works
  8. 8 South Korea 25 works
  9. 9 Italy 24 works
  10. 10 France 22 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 63.6%United States: 15.2%Japan: 5.1%India: 3.1%6 others listed: 13.1%64%largest
China796 · 63.6%United States190 · 15.2%Japan63 · 5.1%India39 · 3.1%6 others listed164 · 13.1%

Shares of the rows listed above, not of the whole node.

Which institutions lead Clusterin in disease pathology research?

By volume in 2022-now, Sun Yat-sen University publishes the most Clusterin in disease pathology research, followed by Nanjing Medical University and Shanghai Jiao Tong University.

By volume, 2022-now

  1. 1 Sun Yat-sen UniversityChina 21 works
  2. 2 Nanjing Medical UniversityChina 19 works
  3. 3 Shanghai Jiao Tong UniversityChina 19 works
  4. 4 Zhejiang UniversityChina 17 works
  5. 5 Central South UniversityChina 15 works
  6. 6 Fudan UniversityChina 14 works
  7. 7 Harbin Medical UniversityChina 14 works
  8. 8 Zhengzhou UniversityChina 13 works
  9. 9 Capital Medical UniversityChina 13 works
  10. 10 Wuhan UniversityChina 13 works

Who are the leading researchers in Clusterin in disease pathology?

The most-cited researchers publishing on Clusterin in disease pathology include John Q. Trojanowski, Luigi Ferrucci and Amirhossein Sahebkar.

  1. 1 John Q. Trojanowski United States 286k citations
  2. 2 Luigi Ferrucci United States 281k citations
  3. 3 Amirhossein Sahebkar Iran 258k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Clusterin in disease pathology?

The most cited paper in Clusterin in disease pathology is "Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease" (Paulina V. Arriagada, John H. Growdon, E. Tessa Hedley‐Whyte et al., 1992), with 2,723 citations. Next come "What are biomarkers?" (2,054) and "Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer" (1,774).

Most cited papers
#PaperReleasedCitations
1 Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease Paulina V. Arriagada, John H. Growdon, E. Tessa Hedley‐Whyte et al. · Neurology Mar 1992 2,723
2 What are biomarkers? Kyle Strimbu, Jorge A. Tavel · Current Opinion in HIV and AIDS Open access 21 Aug 2010 2,054
3 Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer Balázs Győrffy · Computational and Structural Biotechnology Journal Open access 2021 1,774
4 Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers Susanne Schöttler, Greta Becker, Svenja Winzen et al. · Nature Nanotechnology 12 Feb 2016 1,267
5 Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. D G Bostwick, D J Grignon, M. Elizabeth H. Hammond et al. · PubMed Jul 2000 1,246
All 100 most cited papers, with filters and sorting

Where is Clusterin in disease pathology research done?

The largest centres of Clusterin in disease pathology research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and Hangzhou (China). Among places with at least 20 works in it, it is an unusually large share of all research in Changsha.

Largest cities, 2022-now

  1. 1 BeijingChina 66 works
  2. 2 ShanghaiChina 64 works
  3. 3 GuangzhouChina 51 works
  4. 4 HangzhouChina 35 works
  5. 5 ChangshaChina 33 works
  6. 6 NanjingChina 30 works
  7. 7 WuhanChina 29 works
  8. 8 ChengduChina 22 works
  9. 9 JinanChina 21 works
  10. 10 Xi'anChina 18 works

Where it is the local speciality

  1. ChangshaCN · 33.2 works4.6×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Clusterin in disease pathology than the world average.

See Clusterin in disease pathology on the map

Where is the best place to study Clusterin in disease pathology?

Among universities, judged by research, Nanchang University, Shanghai Jiao Tong University and Zhejiang University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 14.29%fractional works in this field (log) →share of work in the world top 10% →Nanchang UniversityZhejiang UniversityShanghai Jiao Tong U…Harbin Medical Unive…
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Nanchang UniversityChina 70.519.4%11.2×11 +565.0%
2Shanghai Jiao Tong UniversityChina 66.011.7%4.9×19 +56.7%
3Zhejiang UniversityChina 65.615.3%4.7×17 +235.4%
4Harbin Medical UniversityChina 63.911.3%30.4×14 +124.6%
5Sun Yat-sen UniversityChina 63.610.9%7.8×21 +91.1%
6Wuhan UniversityChina 62.917.7%6.8×13 +112.0%
7Harvard UniversityUnited States 60.514.4%2.4×10 +52.9%
8Fudan UniversityChina 57.113.8%6.7×14 +144.8%
9Southern Medical UniversityChina 55.518.7%12.8×10 -
10Nanjing Medical UniversityChina 55.49.7%16.4×19 +281.6%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Clusterin in disease pathology, country by country

Is Clusterin in disease pathology research growing?

Output in 2022-2025 was 69% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Clusterin in disease pathology.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Clusterin in disease pathology as a percentage of every work published that year, 0.0048% in 2024.

still counting0.0025%0.0050%0.0075%Clusterin in disease pathology0.0070% in 202519801990200020102020

Fractional works of Clusterin in disease pathology over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Clusterin in disease pathology10.0% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Clusterin in disease pathology. Posts are plain text and can be reported.